AI assistant
Sending…
Teva Pharmaceutical Industries Ltd. — Director's Dealing 2022
Jun 16, 2022
7082_dirs_2022-06-16_82046c21-dc42-4077-a5ba-7119a3d5c97d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK: 0000818686
Period of Report: 2022-06-14
Reporting Person: Vergis Janet S. (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-06-14 | Ordinary Shares | M | 14479 | — | Acquired | 27147 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-06-14 | Restricted Share Units | $ | M | 14479 | Disposed | Ordinary Shares (14479) | Direct |
Footnotes
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3: Restricted share units were granted on June 14, 2021 and vested on June 14, 2022.